Palisade Bio Receives FDA Clearance For Its Investigational New Drug Application For PALI-2108 To Treat Crohn's Disease; First Participant Enrollment Anticipated In Q1 Next Year

Palisade Bio, Inc. (NASDAQ: PALI) has received FDA clearance for its Investigational New Drug application for PALI-2108, allowing the company to start the Phase 2 ASCENTRA-CD clinical trial for treating moderate to severe Crohn's disease. The first participant enrollment is expected in the first quarter of next year.